BVF as of June 30, 2016
Portfolio Holdings for BVF
BVF holds 34 positions in its portfolio as reported in the June 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 12.5 | $59M | 2.9M | 20.25 | |
| Cytokinetics (CYTK) | 10.1 | $47M | 5.0M | 9.49 | |
| Chemocentryx | 7.8 | $37M | 8.2M | 4.49 | |
| Exelixis Inc cnv | 7.2 | $34M | 23M | 1.49 | |
| Concert Pharmaceuticals I equity | 6.6 | $31M | 2.8M | 11.23 | |
| Array BioPharma | 6.3 | $29M | 8.3M | 3.56 | |
| Forward Pharma A/s | 5.5 | $26M | 1.4M | 18.17 | |
| Ionis Pharmaceuticals (IONS) | 4.2 | $20M | 850k | 23.29 | |
| Glycomimetics (GLYC) | 3.8 | $18M | 2.4M | 7.27 | |
| Cascadian Therapeutics | 3.8 | $18M | 19M | 0.94 | |
| Oncomed Pharmaceuticals | 3.5 | $17M | 1.3M | 12.31 | |
| Tobira Therapeutics Inc Common Stock Usd 0.0001 | 3.4 | $16M | 1.3M | 12.56 | |
| Cti Biopharma | 3.2 | $15M | 45M | 0.34 | |
| ArQule | 3.0 | $14M | 7.5M | 1.90 | |
| Xenon Pharmaceuticals (XENE) | 2.2 | $11M | 1.8M | 5.92 | |
| Nivalis Therapeutics | 1.9 | $8.9M | 1.9M | 4.60 | |
| Vitae Pharmaceuticals | 1.8 | $8.2M | 761k | 10.79 | |
| Paratek Pharmaceuticals | 1.7 | $8.0M | 575k | 13.91 | |
| Infinity Pharmaceuticals (INFIQ) | 1.5 | $6.9M | 5.2M | 1.33 | |
| GTx | 1.4 | $6.3M | 12M | 0.55 | |
| Cytomx Therapeutics (CTMX) | 1.3 | $6.2M | 606k | 10.22 | |
| Aduro Biotech | 1.2 | $5.8M | 514k | 11.31 | |
| Macrogenics (MGNX) | 1.1 | $5.4M | 200k | 26.99 | |
| Esperion Therapeutics (ESPR) | 1.1 | $4.9M | 499k | 9.88 | |
| Pain Therapeutics | 1.0 | $4.7M | 2.1M | 2.19 | |
| Qlt | 0.7 | $3.2M | 2.3M | 1.42 | |
| Sunesis Pharmaceuticals | 0.6 | $2.6M | 4.8M | 0.55 | |
| Orexigen Therapeutics | 0.5 | $2.3M | 5.3M | 0.43 | |
| Mast Therapeutics | 0.4 | $1.7M | 3.7M | 0.47 | |
| Catalyst Biosciences | 0.3 | $1.5M | 971k | 1.52 | |
| Globeimmune (GBIM) | 0.3 | $1.3M | 658k | 1.94 | |
| Calithera Biosciences | 0.1 | $450k | 121k | 3.71 | |
| Pieris Pharmaceuticals (PIRS) | 0.1 | $389k | 241k | 1.61 | |
| Aviragen Therapeutics | 0.1 | $292k | 208k | 1.40 |
